Harrow Q2 Earnings Call Highlights
Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2H gross margin trajectory, monitor execution risk around commercial ramp and SG&A, and price the probability/timing of TYRVAYA closing and 2027 accretion.
Market read
Management guidance and deal/pipeline specifics can drive re-rating of Harrow’s ophthalmic growth and margin recovery narrative, with execution and timing risks.
What to watch
Gross margin guidance depends on revenue cycle normalization and product mix; commercial investment (SG&A) and integration of Viatris Eye Care personnel could pressure results before benefits show up.
Background
The piece summarizes Harrow’s Q2 earnings call, covering revenue/margins, product launches and commercial expansion, a pending TYRVAYA acquisition, and pipeline regulatory milestones.
Ticker impact
Harrow’s Q2 call highlights IHEEZO revenue dynamics, margin outlook, BYOOVIZ launch, and plans to acquire TYRVAYA rights using $30M cash.
Moderate upside bias if investors view margin recovery and TYRVAYA accretion as credible; volatility possible around deal closing timing and integration costs.
The article provides specific management guidance (gross margin returning to high-70% range in 2H, TYRVAYA revenue expectations for 2027, and cash use for upfront consideration) plus concrete product and pipeline updates that can re-rate the story.
Market effects
Ophthalmology biopharma sentiment may improve if margin normalization and dry-eye commercial expansion appear to be working, reinforcing the value of retina and dry-eye franchises.
Primarily US-focused read-through for NASDAQ-listed ophthalmic peers; limited direct regional spillover beyond investor sentiment.
TYRVAYA rights expansion includes China and additional countries under review, which can influence global dry-eye competitive expectations.
Counterpoint
The call emphasizes normalization and future accretion, but 2026 TYRVAYA contribution is expected to be modest, so near-term fundamentals may not materially change until later.
Key entities
- companyHarrow Health, Inc.
Commercial-stage ophthalmic biopharma; reported Q2 highlights and provided 2H margin outlook plus TYRVAYA acquisition plans.
- productTYRVAYA
Dry eye treatment; Harrow plans to acquire global rights subject to closing, targeting >$30M revenue in 2027.
- productIHEEZO
Wholesaler stocking-driven revenue in Q2; management says channel inventory normalized and pricing increased effective July 1.
- productBYOOVIZ
Retinal biosimilar launched July 1 with encouraging early physician engagement.
- pipelineG-MELT (MELT-300)
IV-free, opioid-free procedural sedation; pre-NDA meeting with FDA scheduled early Q4, NDA in 1H 2027.
